This content is from: Premium


Here are the top U.S. analysts who have adapted their research coverage to help hedge funds generate alpha.

ON MAY 10, 2007, the U.S. Food and Drug Administration held a nine-hour meeting over potential labeling changes for Aranesp, Amgen's best-selling drug, used to treat chemotherapy-induced anemia. Restrictions could annihilate sales at the Thousand Oaks, California­based biotechnology giant. Early the next morning hedge fund managers were scrambling to determine the impact the meeting would have

To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.

Related Content